US District Judge Dan Polster will hear arguments next March in three lawsuits brought by Ohio municipalities and counties against opioid-drug manufacturers and distributors Purdue Pharma, Johnson & Johnson, Teva Pharmaceutical Industries, Endo, AmerisourceBergen, Cardinal Health and McKesson.
A study published in the Journal of Oncology Practice found no link between the monthly or incremental costs of new cancer drugs and their clinical benefits. The authors looked at 42 clinical trials for medications approved from 2006 to 2015, finding that average monthly costs of new oncology drugs rose to $15,535 in 2015 from $7,103 in 2006, while the difference in cost between new drugs and those they were intended to replace climbed to $161,141 from $30,447.
Analysts expect Amgen and Novartis to set the price on a new type of migraine drug at around $8,500, which the Institute for Clinical and Economic Review said may be cost-effective for treating chronic migraines but not episodic migraines. The institute said the price would not be cost-effective for Teva's new drug for either type of migraine.
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.
Contact PCMA Charles Cote
Vice President, Strategic Communications